Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca

Animals Calcium Channels, T-Type Cannabinoid Receptor Agonists / pharmacology Cannabinoids / chemistry Hypothermia Indazoles / pharmacology Mice Receptor, Cannabinoid, CB1 Receptor, Cannabinoid, CB2 Receptors, Cannabinoid
BEPIRAPIM MEPIRAPIM NNL calcium channel cannabinoid pharmacology

Journal

ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337

Informations de publication

Date de publication:
04 05 2022
Historique:
pubmed: 21 4 2022
medline: 6 5 2022
entrez: 20 4 2022
Statut: ppublish

Résumé

Synthetic cannabinoid receptor agonists (SCRAs) are a large and growing class of new psychoactive substances (NPSs). Two recently identified compounds, MEPIRAPIM and 5F-BEPIRAPIM (NNL-2), have not been confirmed as agonists of either cannabinoid receptor subtype but share structural similarities with both SCRAs and a class of T-type calcium channel (Ca

Identifiants

DOI: 10.1021/acschemneuro.1c00822 PMID: 35442021
pubmed: 35442021
doi: 10.1021/acschemneuro.1c00822
doi:

Substances chimiques

Calcium Channels, T-Type 0
Cannabinoid Receptor Agonists 0
Cannabinoids 0
Indazoles 0
Receptor, Cannabinoid, CB1 0
Receptor, Cannabinoid, CB2 0
Receptors, Cannabinoid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1395-1409

Auteurs

Richard C Kevin (RC)

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
School of Pharmacy, The University of Sydney, NSW 2006, Australia.
ORCID: 0000-0002-4912-4499

Somayeh Mirlohi (S)

Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia.

Jamie J Manning (JJ)

Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.

Rochelle Boyd (R)

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
School of Chemistry, The University of Sydney, NSW 2006, Australia.

Elizabeth A Cairns (EA)

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
School of Psychology, The University of Sydney, NSW 2006, Australia.

Adam Ametovski (A)

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
School of Chemistry, The University of Sydney, NSW 2006, Australia.

Felcia Lai (F)

School of Pharmacy, The University of Sydney, NSW 2006, Australia.

Jia Lin Luo (JL)

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
School of Psychology, The University of Sydney, NSW 2006, Australia.

William Jorgensen (W)

School of Chemistry, The University of Sydney, NSW 2006, Australia.
ORCID: 0000-0002-9990-6894

Ross Ellison (R)

Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, California 94143, United States.

Roy R Gerona (RR)

Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, California 94143, United States.

David E Hibbs (DE)

School of Pharmacy, The University of Sydney, NSW 2006, Australia.
ORCID: 0000-0002-2635-2990

Iain S McGregor (IS)

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
School of Psychology, The University of Sydney, NSW 2006, Australia.

Michelle Glass (M)

Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
ORCID: 0000-0002-5997-6898

Mark Connor (M)

Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia.
ORCID: 0000-0003-2538-2001

Chris Bladen (C)

Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia.
Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.

Gerald W Zamponi (GW)

Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
ORCID: 0000-0002-0644-9066

Samuel D Banister (SD)

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
School of Chemistry, The University of Sydney, NSW 2006, Australia.
ORCID: 0000-0002-4690-4318

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Canaux ioniques › Canaux calciques › Canaux calciques de type T › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Modulateurs des récepteurs de cannabinoïdes › Agonistes des récepteurs de cannabinoïdes › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Cannabinoïdes › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Troubles de la température corporelle › Hypothermie › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indazoles › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB1 › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB2 › Putative Synthetic Cannabinoids MEPIRAPIM,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Putative Synthetic Cannabinoids MEPIRAPIM,...